The evolution of SARS-CoV-2 emphasizes the urgent need for broad-spectrum antivirals targeting conserved viral enzymes such as the main protease (Mpro). Olea europaea (European olive) and Canarium album (Chinese olive) contain diverse bioactive phytochemicals with potential antiviral properties, yet their mechanistic relevance to SARS-CoV-2 remains undefined. To identify bioactive phytochemicals from European and Chinese olives and explore their mechanisms in inhibiting SARS-CoV-2 Mpro. Sixty-six phytochemicals were screened using a FRET-based Mpro assay. Potent candidates were further evaluated by IC50 determination, enzyme kinetics, cytotoxicity, and live-virus assays. Binding interactions were characterized using ITC and STD-NMR, while stereochemistry-dependent behavior was examined through chiral chromatographic analysis, molecular docking and molecular dynamics simulations. Five compounds-Oleuropein Aglycone Aldehyde (OAA), Hydroxytyrosol (HT), Oleuropein (OL), Oleuropeinic acid (OPA), and Oleuroside (OS)-displayed significant Mpro inhibition (IC50: 4.8-15.7 μM; Ki: 3.4-18.0 μM). OAA was the most potent inhibitor through a competitive mechanism with antiviral activity against the ancestral strain (EC50 = 19.8 μM) and Omicron/Delta variants. ITC confirmed 1:1 binding (Kd = 13.5 μM), and STD-NMR showed that both 8S and 8R diastereomers interact with Mpro. Molecular modeling supported stable engagement within the catalytic pocket, where the 8S adopted an extended, multi-contact orientation, and the 8R occupied a compact subpocket. OAA is a natural SARS-CoV-2 Mpro inhibitor exhibiting stable binding, stereochemical preference, and cross-variant antiviral activity. Its defined biochemical mechanism and stable structural engagement position OAA as a promising scaffold for antiviral development.
The therapeutic application of peptides has expanded considerably in clinical and regenerative medicine; however, the contribution of peptide metabolites to therapeutic efficacy remains poorly understood. We previously identified N -acetyl- l -leucyl- l -lysine (Ac-LK) as the major metabolite of TB-500 by metabolic profiling and hypothesized that it contributes to the biological activity of the parent peptide. Initial screening demonstrated that Ac-LK exhibited greater SARS-CoV-2 main protease inhibitory activity than TB-500, the other identified metabolites, and the constituent amino acids. We therefore systematically characterized Ac-LK using cellular uptake, endothelial cell functional assays, proteomic profiling, and in vivo wound healing. Under the experimental conditions employed, Ac-LK exhibited enhanced protection against hypoxia/reoxygenation-induced injury, stronger promigratory and barrier-stabilizing activities, broader regulation of pathways related to cytoskeletal organization, cadherin-mediated adhesion, and protein translation, and accelerated wound healing. Collectively, these findings identify Ac-LK as a biologically active metabolite of TB-500 and support the hypothesis that metabolic conversion contributes to the therapeutic actions of the parent peptide.